Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 2
2009 1
2010 2
2011 1
2012 1
2014 1
2015 5
2016 2
2018 2
2020 1
2021 2
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, Campbell H, Wan H, Teal V, Jin Xu Z, Asante-Appiah E, Sklar P, Teppler H, Lahoulou R; DRIVE-FORWARD and DRIVE-AHEAD collaborators. Orkin C, et al. Lancet HIV. 2024 Feb;11(2):e75-e85. doi: 10.1016/S2352-3018(23)00258-8. Epub 2023 Dec 20. Lancet HIV. 2024. PMID: 38141637 Clinical Trial.
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. HIV Med. 2015. PMID: 25711317 Free PMC article. No abstract available.
Incidence and risk factors for suicide, death due to substance use, and violent/accidental death in people with HIV.
Tusch ES, Ryom L, Fursa O, Peters L, Østergaard L, Florence E, Edwards S, Hoffmann C, Sambatakou H, Reiss P, Shahar E, Reikvam DH, Schmied B, Paduta D, Yakovlev A, Szlávik J, Ranin J, Zilmer K, Uždaviniene V, Pelchen-Matthews A, Mocroft A, Reekie J. Tusch ES, et al. Among authors: schmied b. AIDS. 2023 Jan 1;37(1):161-171. doi: 10.1097/QAD.0000000000003402. Epub 2022 Oct 11. AIDS. 2023. PMID: 36250262
Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations.
Laut KG, Shepherd L, Gottfredsson M, Sedlacek D, Knysz B, Begovac J, Radoi R, Schmied B, Chkhartishvili N, Florence E, Ristola M, Fätkenheuer G, Mulcahy F, Schmid P, Kuzovatova E, Paduta D, Smidt J, Domingo P, Szlávik J, Lundgren J, Mocroft A, Kirk O; EuroSIDA study group. Laut KG, et al. Among authors: schmied b. AIDS. 2018 Nov 28;32(18):2807-2819. doi: 10.1097/QAD.0000000000002035. AIDS. 2018. PMID: 30289816
Hypersensitivity reactions, hepatotoxicity, and other discontinuations in persons receiving integrase strand transfer inhibitors: results from the EuroSIDA study.
Pelchen-Matthews A, Larsen JF, Shepherd L, Begovac J, Pedersen K, De Wit S, Horban A, Jablonowska E, Johnson M, Khromova I, Losso MH, Nielsen LN, Ridolfo AL, Schmied B, Stephan C, Yust I, Curtis L, Vannappagari V, Ragone L, Roen A, Raben D, Kirk O, Peters L, Mocroft A; EuroSIDA Study Group. Pelchen-Matthews A, et al. Among authors: schmied b. HIV Res Clin Pract. 2021 Dec;22(6):160-168. Epub 2021 Nov 15. HIV Res Clin Pract. 2021. PMID: 34779362
A Lower CD4 Count Predicts Most Causes of Death except Cardiovascular Deaths. The Austrian HIV Cohort Study.
Leierer G, Rieger A, Schmied B, Sarcletti M, Öllinger A, Wallner E, Egle A, Kanatschnig M, Zoufaly A, Atzl M, Rappold M, El-Khatib Z, Ledergerber B, Zangerle R, On Behalf Of The Austrian Hiv Cohort Study Group. Leierer G, et al. Among authors: schmied b. Int J Environ Res Public Health. 2021 Nov 28;18(23):12532. doi: 10.3390/ijerph182312532. Int J Environ Res Public Health. 2021. PMID: 34886257 Free PMC article.
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial.
Dickinson L, Gurjar R, Stöhr W, Bonora S, Owen A, D'Avolio A, Cursley A, Molina JM, Fäetkenheuer G, Vandekerckhove L, Di Perri G, Pozniak A, Richert L, Raffi F, Boffito M; NEAT001/ANRS143 Study Group. Dickinson L, et al. J Antimicrob Chemother. 2020 Mar 1;75(3):628-639. doi: 10.1093/jac/dkz479. J Antimicrob Chemother. 2020. PMID: 31754703 Clinical Trial.
Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.
Eron JJ Jr, Lelievre JD, Kalayjian R, Slim J, Wurapa AK, Stephens JL, McDonald C, Cua E, Wilkin A, Schmied B, McKellar M, Cox S, Majeed SR, Jiang S, Cheng A, Das M, SenGupta D. Eron JJ Jr, et al. Among authors: schmied b. Lancet HIV. 2018 Dec 13:S2352-3018(18)30296-0. doi: 10.1016/S2352-3018(18)30296-0. Online ahead of print. Lancet HIV. 2018. PMID: 30555051
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.
Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin AG, Raffi F; NEAT 001/ANRS 143 Study Group. Lambert-Niclot S, et al. J Antimicrob Chemother. 2016 Apr;71(4):1056-62. doi: 10.1093/jac/dkv427. Epub 2015 Dec 24. J Antimicrob Chemother. 2016. PMID: 26702926 Free article. Clinical Trial.
20 results